MEDNAX, Inc. (NYSE:MD) Expected to Announce Earnings of $0.16 Per Share


Share on StockTwits

Equities research analysts expect that MEDNAX, Inc. (NYSE:MD) will post $0.16 earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for MEDNAX’s earnings, with estimates ranging from $0.07 to $0.36. MEDNAX posted earnings per share of $0.32 in the same quarter last year, which would suggest a negative year-over-year growth rate of 50%. The company is scheduled to announce its next quarterly earnings report before the market opens on Friday, May 7th.

On average, analysts expect that MEDNAX will report full year earnings of $1.30 per share for the current fiscal year, with EPS estimates ranging from $1.08 to $1.58. For the next year, analysts expect that the firm will post earnings of $1.61 per share, with EPS estimates ranging from $1.53 to $1.76. Zacks’ earnings per share averages are an average based on a survey of research firms that follow MEDNAX.

MEDNAX (NYSE:MD) last issued its quarterly earnings data on Thursday, February 18th. The company reported $0.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.26 by ($0.01). The company had revenue of $416.63 million during the quarter, compared to analysts’ expectations of $456.01 million. MEDNAX had a negative net margin of 26.57% and a positive return on equity of 12.27%.

MD has been the topic of a number of recent research reports. Citigroup cut their price target on shares of MEDNAX from $24.00 to $22.00 in a research note on Friday, February 19th. Zacks Investment Research downgraded MEDNAX from a “hold” rating to a “strong sell” rating and set a $21.00 price objective for the company. in a research report on Tuesday, April 20th. Truist upped their price target on MEDNAX from $22.00 to $28.00 in a report on Wednesday, April 14th. Credit Suisse Group lowered their price target on MEDNAX from $26.00 to $25.00 and set an “outperform” rating for the company in a report on Thursday, February 25th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on MEDNAX from $14.00 to $17.50 and gave the company a “sell” rating in a report on Friday, February 19th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $19.65.

In other MEDNAX news, Director Roger Md Medel sold 100,000 shares of the business’s stock in a transaction that occurred on Thursday, April 1st. The stock was sold at an average price of $25.40, for a total value of $2,540,000.00. Following the completion of the sale, the director now owns 1,318,439 shares in the company, valued at $33,488,350.60. The sale was disclosed in a document filed with the SEC, which is available through this link. 3.70% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in MD. Morgan Stanley raised its stake in shares of MEDNAX by 68.2% during the third quarter. Morgan Stanley now owns 198,583 shares of the company’s stock worth $3,234,000 after purchasing an additional 80,495 shares during the last quarter. Great West Life Assurance Co. Can raised its stake in shares of MEDNAX by 2.6% during the third quarter. Great West Life Assurance Co. Can now owns 42,701 shares of the company’s stock worth $695,000 after purchasing an additional 1,071 shares during the last quarter. Paces Ferry Wealth Advisors LLC purchased a new stake in shares of MEDNAX during the third quarter worth approximately $40,000. Sei Investments Co. raised its stake in shares of MEDNAX by 3.5% during the third quarter. Sei Investments Co. now owns 284,861 shares of the company’s stock worth $4,635,000 after purchasing an additional 9,590 shares during the last quarter. Finally, State of Alaska Department of Revenue raised its stake in shares of MEDNAX by 357.8% during the fourth quarter. State of Alaska Department of Revenue now owns 66,626 shares of the company’s stock worth $1,635,000 after purchasing an additional 52,072 shares during the last quarter. Institutional investors and hedge funds own 95.74% of the company’s stock.

NYSE:MD traded down $0.29 on Tuesday, reaching $26.18. 770,394 shares of the company’s stock were exchanged, compared to its average volume of 941,073. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 2.16. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of -3.02, a price-to-earnings-growth ratio of 1.70 and a beta of 2.09. The business has a fifty day moving average of $26.34 and a 200-day moving average of $23.25. MEDNAX has a 52-week low of $11.62 and a 52-week high of $29.25.

MEDNAX Company Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.

Featured Article: How is the S&P 500 index different from the DJIA?

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.